A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 01 Jun 2018
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Capmatinib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 01 Feb 2017 This trial was discontinued in Netherlands as per European Clinical Trials Database record.
- 12 Jan 2017 Trial has been completed in Spain (end date: 2016-12-23), according to the European Clinical Trials Database record.
- 01 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.